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Persistent Systemic Inflammation in Unstable Angina
s Largely Unrelated to the Atherothrombotic Burden
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OBJECTIVES The aim of this study was to assess the relationship between systemic inflammation,
atherosclerosis, and thrombosis in two distinct clinical models of atherothrombosis.
BACKGROUND Persistent unstable angina (UA) is commonly associated with coronary thrombosis and
persistent systemic inflammation.
METHODS We assessed circulating markers of activation of the thrombotic and fibrinolytic cascades and
systemic soluble and cellular markers of inflammation on admission in 40 patients with
persisting UA (Braunwald class IIIB; group 1) and 30 patients with Leriche-Fontaine stage
IIB-III peripheral artery disease awaiting revascularization (group 2).
RESULTS The extent of atherosclerosis (p 0.01) and activation of the coagulation system were greater
in group 2, which had higher thrombin-antithrombin III complexes and D-dimer levels (2.7
and 24.4 g/l, respectively), than in group 1 (2.0 g/l and 12.9 g/l, p  0.02 and p 
0.0001, respectively). In contrast, C-reactive protein and interleukin-6 levels were higher in
group 1 (7.6 pg/ml and 7.8 pg/ml, respectively) than in group 2 (4.5 pg/ml and 3.0 pg/ml,
p  0.01 and p  0.03, respectively). Moreover, neutrophil activation was only found in
group 1 (neutrophil myeloperoxidase content 4.0 arbitrary units vs. 3.4 arbitrary units in
group 2, p  0.0001). These differences persisted during the initial three days of
hospitalization.
CONCLUSIONS Such a large, consistent discrepancy between atherothrombotic burden and systemic inflam-
mation suggests that atherothrombosis, by itself, is an unlikely cause of persisting, recurring
UA. An understanding of the primary inflammatory mechanisms of persistent and recurrent
coronary instability could open the way to novel therapeutic strategies. (J Am Coll Cardiol

























rhe spectrum of clinical presentation of acute coronary
yndromes is varied. At one extreme end of the spectrum,
ome patients present with acute myocardial infarction not
receded by anginal symptoms and, after this event, may
emain totally asymptomatic for years or decades. At the
ther end, some patients present with infarction preceded
See page 244
nd followed by unstable angina (UA). Indeed, UA, which
owadays accounts for about 50% of coronary care admis-
ions, is typically characterized by persistence or recurrence
f symptoms and by an incumbent threat of myocardial
nfarction and sudden death over periods of weeks and
onths. The actual triggers of the occasional transition
rom stable to unstable atherosclerosis may not be the same
n these two extreme groups. By definition, angina is
onsidered “unstable” when onset or sudden worsening of
ymptoms dates back up to two months before admission
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004, accepted September 3, 2004.1), and the average risk of major cardiac events at four to six
onths exceeds 10% under the current optimal medical (2)
r interventional strategies (3). Eventually, only after six
onths, the increased risk transiently conferred by instabil-
ty reverts back to that of stable or “quiescent” phases of
schemic heart disease. Coronary thrombi composed of
ayers of different ages are common at autopsy in unstable
atients (4), consistent with a “staccato” pattern of clinical
xacerbations of instability and with a nearly 50% reduction
f infarction rates achieved by antiplatelet and antithrom-
otic treatments (1). However, thrombosis, by itself, may
ot be the only plausible explanation of the long persistence
nd common recurrence of coronary instability. A possible
ole of an acute coronary inflammatory process is suggested
y: 1) elevated levels of circulating inflammatory markers
bserved in patients with refractory UA and with acute
nfarction preceded by UA (5–9); 2) persistence of elevated
-reactive protein (CRP) serum levels after acute instability
ssociated with a seven-fold greater risk of recurring UA or
f infarction (10,11); and 3) the adverse prognostic value of
ncreasing levels of interleukin (IL)-1 receptor antagonist
nd IL-6 during the first two days after admission in
atients with persisting UA (12).
Thus, the intriguing association between coronary
hrombosis and inflammation observed in patients with UA
aises the question of whether systemically detectable
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January 18, 2005:238–43 Atherothrombosis, Inflammation, and UAosis or whether it may reflect independent, primary causal
echanisms of inflammation directly responsible for per-
isting, recurrent coronary instability.
To investigate the relative role of atherothrombosis and
hat of primary inflammatory triggers in UA, we compared
he levels of circulating markers of systemically detectable
hrombotic and inflammatory activation in two distinct
linical syndromes, both characterized by atherothrombosis.
We assessed systemic soluble and cellular markers of
nflammation together with markers of activation of the
hrombotic and fibrinolytic cascades and seropositivity to
utative infectious agents in 40 patients with Braunwald
lass IIIB UA and negative troponin T, as well as in 30
atients with Leriche-Fontaine stage IIB-III peripheral
rtery disease (PAD) awaiting revascularization procedures,
s potential distinct clinical models of atherothrombotic
iseases.
ETHODS
tudy population. GROUP 1: UNSTABLE ANGINA. We
nrolled 40 consecutive patients (34 men, age 60  12
ears) admitted to our coronary care unit with Braunwald
lass IIIB UA, without evidence of acute myocardial necro-
is detected by troponin T release, and submitted to coro-
ary angiography. We excluded patients with positive tro-
onin T (0.1 mg/l), known or suspected thrombotic
isorders, malignancy, infection, inflammatory disease, or
ecent surgery or trauma (4 weeks). All patients were
reated with aspirin, intravenous nitrates, calcium antago-
ists, and/or beta-blockers. Heparin was not used as a
rst-step treatment. In addition, we also excluded patients
ith Doppler evidence of PAD or a systolic ankle/brachial
ressure ratio 0.95.
ROUP 2: PERIPHERAL ARTERY DISEASE. We enrolled 30
onsecutive patients (21 men, age 63  16 years) with
eriche-Fontaine stage IIB to III PAD with claudication
ppearing after 100 m of walking, admitted for revascu-
arization by a Rotablator percutaneous procedure or sur-
ery. General exclusion criteria adopted for UA patients
ere also applied to PAD. In addition, we also excluded
atients with evidence of trophic limb lesions and those
ith a previous myocardial infarction and echocardiographic
vidence of regional wall motion alteration at rest or after a
ipyridamole stress test.
nformed consent. The Ethics Committee of the Catholic
niversity of Rome approved the protocol, and all patients
Abbreviations and Acronyms
CRP  C-reactive protein
IL  interleukin
PAD  peripheral artery disease
UA  unstable anginaave their written, informed consent. nlood sampling and laboratory methods. The number of
oronary and peripheral artery flow-limiting stenoses with
70% diameter reduction and total occlusion and of steno-
es between 50% and 70% was assessed visually by two
ndependent observers, and discordant findings were re-
olved by a third observer.
Peripheral blood samples were taken on hospital admis-
ion and after 6, 12, 24, 48, and 72 h in both groups of
atients.
We measured high-sensitivity CRP and IL-6 as markers
f an acute-phase response, neutrophil myeloperoxidase
ontent as an indicator of neutrophil activation, thrombin-
ntithrombin III complexes and prothrombin fragment
2 as markers of thrombin generation, and D-dimers as
arkers of formed intravascular fibrin undergoing lysis.
eropositivity for Chlamydia pneumoniae, cytomegalovirus,
nd Helicobacter pylori was also assessed. Troponin T, a
pecific marker of myocardial necrosis, was measured to rule
ut the possible role of myocardial cell damage in inducing
he inflammatory response.
Samples for thrombin-antithrombin III complexes, pro-
hrombin fragment 12, D-dimers, and IL-6 were immedi-
tely transferred into pre-cooled tubes containing citrate, the-
phylline, adenosine, and dipyridamole (CTAD tubes; Dade-
ehring, Marburg, Germany) and centrifuged at 2,000 g and
t 4°C for 20 min. Plasma aliquots were stored at 80°C.
ommercially available ELISA assays (Enzygnost thrombin-
ntithrombin III complex, micro-prothrombin fragment 12,
nd D-dimer ELISA kit, Dade-Behring; Quantikine human
L-6, R&D Systems, Minneapolis, Minnesota) were used.
Serum samples were obtained for CRP and troponin T
nalysis and for assessment of seropositivity for C. pneumoniae,
ytomegalovirus, and H. pylori. C-reactive protein was
ssayed in an ultra-sensitive CRP assay by nephelometry
BN-II, Dade-Behring) with a sensitivity of 0.2 mg/l.
roponin T was measured by a commercial enzyme immu-
oassay (Boehringer Mannheim, Mannheim, Germany).
eropositivity for C. pneumoniae was assessed by the micro-
mmunofluorescence method (Chlamydia MIF kit, MRL
iagnostics, Cypress, California); seropositivity for C. pneu-
oniae was defined as the presence of specific antibodies at
serum dilution of 1:16. Seropositivity for cytomegalovirus
nd H. pylori was assessed by a commercial ELISA for
pecific immunoglobulin G (Dade-Behring); seropositivity
or cytomegalovirus and H. pylori was defined as the
resence of a serum antibody titer 6 U/l and 10 U/l,
espectively.
Samples for myeloperoxidase intracellular content were
mmediately transferred into tubes containing 1:9 EDTA
olution and quickly analyzed using a Bayer H*3 hematol-
gy analyzer (Bayer-Diagnostic Co., Tarrytown, New
ork), as previously described (8,13). The computer soft-
are calculates an index of intracellular myeloperoxidase
ctivity (intracellular myeloperoxidase index), which quan-
ifies the mean myeloperoxidase activity of the whole
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eutrophils are rich in myeloperoxidase, and negative values
ndicate depletion of myeloperoxidase, due to neutrophil
ctivation and degranulation.
tatistical analysis. As the data were not normally distrib-
ted, non-parametric tests were used. Results are expressed
s the median value, 25% to 75% interquartiles, and range.
he Mann-Whitney U test was used to evaluate differences
etween groups, and discontinuous variables were tested by
he chi-square test. Correlation between variables was as-
essed by the Spearman correlation test. Continuous vari-
bles containing clinical data are expressed as the mean
alue  SD and were evaluated by the Student t test. A p
alue of 0.05 was considered statistically significant. All
ests were two-tailed.
ESULTS
linical variables and angiographic findings. The two
roups were similar in terms of age, gender, smoking status,
ypertension, diabetes, and family history of ischemic heart
isease (Table 1). The number of flow-limiting arterial
tenoses was significantly higher in PAD than in UA
stenosis 70% and occlusion: 5.5  1.6 vs. 2.5  0.9,
espectively; stenoses between 50% and 70%: 4.7  2.3 vs.
.1 0.5, respectively; p 0.01) (Table 1, Fig. 1). In PAD,
he presence of flow-limiting coronary stenoses was ex-
luded by the echocardiographic dipyridamole stress test,
nd in UA, by the presence of peripheral artery stenosis by
systolic ankle/brachial pressure ratio 0.95.
ctivation of thrombotic and fibrinolytic cascade. Acti-
ation of the thrombotic and fibrinolytic cascades was signifi-
antly greater in patients with PAD than in those with UA.
n admission, thrombin-antithrombin III complexes and
-dimers levels were significantly higher in patients with PAD
han in those with UA, being 2.7 g/l (range 0.9 to 47.0 g/l)
ersus 2.0g/l (range 1.2 to 7.4g/l) (p 0.02) (Fig. 2A) and
4.4 g/l (range 9.1 to 182.5 g/l) versus 12.9 g/l (range 1.9
o 60.0 g/l) (p  0.0001) (Fig. 2B), respectively. Moreover,
he levels of thrombin-antithrombin III complexes and








ge (yrs) 60  12 63 16
ale gender 34 (85%) 21 (70%)
amily history of CAD 28 (41%) 6 (20%)
moking 16 (40%) 15 (50%)
ypertension 20 (50%) 15 (50%)
iabetes 13 (32%) 16 (55%)
ypercholesterolemia 22 (55%) 11 (36%)
rterial stenoses 70% and occlusions 2.5 0.9 5.5 1.6*
rterial stenoses 50% to 70% 1.1  0.5 4.7 2.3*
p  0.01 vs. unstable angina. Data are presented as the mean value  SD or
umber (%) of patients.
CAD  coronary artery disease.-dimers remained consistently higher in patients with PAD
o
1han in those with UA throughout the first 72 h of hospital-
zation (p  0.01; data not shown). Prothrombin fragment
2 median levels were not significantly different between UA
1.0 nmol/l, range 0.2 to 8.3 nmol/l) and PAD (1.0 nmol/l,
ange 0.3 to 7.5 nmol/l) (p  NS).
nflammatory markers. In contrast, the inflammatory
arkers CRP and IL-6 were significantly higher in patients
ith UA than in those with PAD, being 7.6 mg/l (range 1.4
o 114 mg/l) versus 4.5 mg/l (range 0.7 to 22.2 mg/l) (p 
.01) for CRP (Fig. 2C) and 7.8 pg/ml (range 3 to 90
g/ml) versus 3.0 pg/ml (range 3 to 15 pg/ml) (p 0.03) for
L-6 (Fig. 2D), respectively. Furthermore, neutrophil acti-
ation was only observed in UA (intracellular myeloperox-
dase index 4.0 arbitrary units [14.5 to 4.7] vs. 3.4
rbitrary units[5 to8.5] in PAD, p 0.0001) (Fig. 2E).
hese differences were maintained throughout the first 72 h
f hospitalization (p  0.01). The neutrophil count did not
iffer between UA and PAD patients. A correlation
etween CRP and IL-6 levels was statistically significant in
A and PAD patients (r  0.45, p  0.01 and r  0.34,
 0.05, respectively). The correlation between the intra-
igure 1. Typical discrepancy in atherosclerotic burden between patient
ith unstable angina (UA) and peripheral artery disease. Right (A) and left
B) coronary angiograms in a patient with UA with a single coronary artery
tenosis in the proximal segment of the left anterior descending coronary
rtery; the C-reactive protein (CRP) level was 57 mg/l and the D-dimer
alue was 3.7 g/l. Femoral (C) and tibial (D) angiograms of a patient with
eripheral vascular disease with multiple atherosclerotic plaques and
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January 18, 2005:238–43 Atherothrombosis, Inflammation, and UAellular myeloperoxidase index and CRP was statistically
ignificant in patients with UA (r  0.62, p  0.03) but
ot in patients with PAD (r  0.13, p  NS). No
orrelation was found between CRP and thrombin-
ntithrombin III complexes, D-dimers, or prothrombin
ragment 12 levels in UA or PAD patients.
The prevalence of seropositivity for infectious agents was
imilar in UA and PAD: 62% versus 40% for C. pneumoniae
p  NS), 89% versus 87% for cytomegalovirus (p  NS),
nd 83% versus 78% for H. pylori (p  NS). There was no
orrelation between CRP levels and antibody titers against
. pneumoniae, cytomegalovirus, and H. pylori in UA or
AD groups.
ISCUSSION
ur study shows that atherothrombosis is unlikely by itself
o account for the elevation of systemic markers of inflam-
ation, which characterizes patients with persisting UA.
ndeed, levels of thrombin-antithrombin III complexes (a
arker of thrombin generation) and D-dimers (a marker of
ormed intravascular fibrin) were nearly twice as high in
atients with severe PAD (Leriche-Fontaine IIB-III)
waiting revascularization than in patients with severe UA
Braunwald class IIIB), consistent with a significantly
reater number of flow-limiting stenosis, total occlusions, or
tenoses 70% and of stenoses 50% to 70%. By contrast,
igure 2. A discrepancy between activation of the coagulation cascade an
eripheral artery disease (PAD) (shaded boxes). Thrombin-antithrombin
atients with PAD than in patients with UA. Conversely, interleukin (IL
atients with UA than in patients with PAD. Moreover, activation of neut
MPXI) (E) was only present in patients with UA. Data are shown as theevels of CRP and IL-6, two major markers of inflamma- iion, were significantly higher in patients with UA than in
atients with PAD. Moreover, neutrophil activation, as
ssessed by its intracellular content of myeloperoxidase, was
nly observed in UA but not in PAD patients and was
inearly correlated with CRP levels. Thus, although severe
AD requiring revascularization procedures is associated
ith a much greater systemic activation of the coagulation
ascade, as compared with UA, it is characterized by a much
maller elevation of CRP and IL-6 levels and by no
etectable neutrophil activation in the peripheral blood.
uch differences remained significant in all successive blood
amples taken up to 72 h after admission.
Elevation of CRP and IL-6 and neutrophil activation
ave been consistently reported in patients with UA but not
n patients with chronic, stable effort angina and a greater
everity of coronary atherosclerosis (6–8) or in patients with
ctive variant angina and a greater ischemic burden (8,14).
t a variance from CRP and IL-6 serum levels, which in
atients with Braunwald class IIIB UA may remain elevated
or several months after discharge (12,15), neutrophil acti-
ation appears limited to the acute symptomatic phase of
nstability of the disease, as it is not found at discharge (8),
nd appears to take place selectively in the coronary vascular
ed of unstable patients (13). These observations are con-
istent with the prognostic value of myeloperoxidase levels
n patients with acute coronary syndromes (16). Conversely,
ulating inflammatory markers in unstable angina (UA) (open boxes) and
mplexes (TAT) (A) and D-dimers (DD) (B) were significantly higher in
D) and C-reactive protein (CRP) levels (C) were significantly higher in
ls, indicated by the significant reduction of their myeloperoxidase content
ian values, 25% to 75% interquartiles, and range.d circ
III co
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17,18).
The greater systemic levels of inflammatory markers in
A, compared with PAD, cannot be explained by differ-
nces in the prevalence of traditional risk factors (Table 1)
r in seropositivity for infectious agents possibly involved in
therosclerotic syndromes, as the prevalence of seropositiv-
ty for C. pneumoniae, cytomegalovirus, and H. pylori was
ot significantly different between patients with UA and
hose with PAD, in agreement with previous studies
19,20).
Our data show significant differences not only in the
agnitude but also in the pattern of systemic markers of
nflammation and activation of the coagulation system in
wo prototypical clinical models of atherothrombosis, UA,
nd peripheral vascular disease. In particular, UA is char-
cterized by a marked systemic up-regulation of inflamma-
ory activation, which considerably exceeds the amount
ttributable to the atherothrombotic burden in PAD. The
ersistence and recurrence of coronary instability is more
uggestive of persistent, recurrent thrombogenic stimuli
han of a process of repair of a single initial injury resulting
rom a fissured or eroded atherosclerotic plaque.
tudy limitations. We assessed the atherosclerotic burden
nly on the basis of the number of stenoses 70% and 50%
o 70%, which was more than double in patients with
eripheral vascular disease (Table 1). However, in postmor-
em studies, the number of coronary flow-limiting stenoses
trongly correlated with the percentage of coronary intimal
urface covered by raised fibrous plaque (21). This correla-
ion is likely to hold true also for PAD. A greater athero-
clerotic burden and a larger endothelial involvement are
onsistent with the markedly higher levels of D-dimers and
hrombin-antithrombin III complexes in patients with
AD also observed in previous studies (22–24). Yet, such
arkedly larger atherosclerotic burden in peripheral vascular
isease was not associated with neutrophil degranulation,
hich was present in UA and with lower high sensitivity
RP and IL-6 serum levels, as compared with UA.
therothrombosis, inflammation, and plaque instability.
ollectively, our findings suggest the hypothesis that the
ecurring phases of coronary instability may not necessarily
evelop when the atherosclerotic burden has reached a
ritical threshold, but may as a result of transient superim-
osed “primary” coronary inflammatory stimuli. Such trig-
ers of instability eventually wane with a return of the
atient to a stable phase and baseline ischemic risk, related
o atherosclerotic and risk factor burden. This hypothesis
ould be consistent with findings of multiple complex
25,26), fissured (27,28), and inflamed (29) coronary artery
laques found in patients with persistent, recurrent insta-
ility, suggestive of simultaneous multifocal plaque instabil-
ty and with widespread coronary inflammation, also involv-
ng angiographically normal arteries (13). Such widespread
oronary inflammation could be related to perturbation of
he immune response (30,31), antigenic mimicry, and au-oimmune mechanisms (32,33). Understanding these in-
ammatory mechanisms could open the way to the devel-
pment of novel therapeutic strategies designed to block
nflammatory triggers of persistent, recurrent coronary
hrombus formation, without interfering heavily with
emostatic mechanisms—so far the only available strategy
o prevent local coronary thrombosis—at the price of an
ncreased risk of bleeding.
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